PHILADELPHIA, Aug. 13, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced its interim financial results for the three months ended June 30, 2007. The net loss for this fiscal quarter was approximately $3,925,000 or $(.05) per share compared to a loss of $5,081,000 or $(.08) per share for 2006. The $1,156,000 decrease in loss was basically due to 1) reduced general and administrative expense of $543,000 primarily related to a reduction in non-cash equity based compensation and lower accounting fees; 2) interest and other income increased $211,000 due to higher interest earned in the current period from the maturities of marketable securities and 3) lower interest expense of $295,000 relating to the amortization of debt discounts on convertible debentures. All convertible debentures were fully retired on June 29, 2007.
